In:
Cancer, Wiley, Vol. 123, No. 13 ( 2017-07), p. 2444-2451
Abstract:
Oral osteoporosis therapy, administered to postmenopausal breast cancer patients (n = 7576) receiving adjuvant aromatase inhibitor therapy (NCIC MA.27 trial), is associated with significantly improved event‐free survival and distant disease–free survival; the time of initiation of osteoporosis therapy (a time‐dependent effect) does not affect the outcome. Osteoporosis therapy does not alter the risk of visceral‐only metastases. See also pages 2392‐4.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v123.13
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1